Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Natco Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹898.00
High
₹918.20
Price Summary
| Previous Close | ₹903.70 |
|---|---|
| Day's Range | ₹898.00 - ₹918.20 |
| Open | ₹898.80 |
| 52 Week Range | ₹789.00 - ₹1,226.80 |
| Volume | 8,08,487 |
| Market Cap | ₹0.02 |
| Previous Close | ₹905.00 |
|---|---|
| Day's Range | ₹894.95 - ₹918.10 |
| Open | ₹894.95 |
| 52 Week Range | ₹789.30 - ₹1,226.10 |
| Volume | 98,506 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,306.30 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.56 |
| Price/Earning (TTM) | 11.29 |
| TTM EPS (₹) | 79.20 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 1.74 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
| Trade Value ( ₹ in Lacs) | 891.48 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.56 |
| Price/Earning (TTM) | 11.29 |
| TTM EPS (₹) | 79.20 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 1.74 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 44295.0 | 12210.0 |
| Expenses | N/A | N/A |
| PBT | 22914.0 | 5059.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 18834.0 | 4060.0 |
About Natco Pharma Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | V C Nannapaneni |
| NSE Symbol | NATCOPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,49,803.33 | 1,861.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,219.17 | 6,705.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,417.21 | 4,524.00 | 3,165.00 - 3,165.00 |
| Apollo Hospitals Enterprise Ltd. | 1,23,273.78 | 8,589.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,115.65 | 1,439.95 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,874.16 | 1,351.00 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,635.65 | 1,100.70 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,263.52 | 2,346.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,217.39 | 1,122.85 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,255.74 | 2,462.80 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Natco Pharma informs about press release
Vivo Bio Tech informs about closure of trading window
Mercury Laboratories informs about newspaper advertisement
Sudeep Pharma informs about closure of trading window
Pursuant to the Code of Conduct on Prevention of Insider Trading of the Company and SEBI (Prohibition of Insider Trading) Regulations, 2015, Sudeep Pharma has informed that the trading window for dealing in the securities of the Company shall be closed for designated persons from Wednesday, 1st July 2026 and shall remain closed till 48 hours after the declaration of the un-audited financial results of the Company for quarter ending on 30th June 2026 and other matters, if any. Accordingly, all Designated Persons and their immediate relatives, directly or indirectly, are prohibited to deal in the securities of the Company during this period. The date of the meeting of the Board of directors to approve the un-audited financial results of the company for the aforementioned quarter, shall be informed to the stock exchanges in due course.
The above information is a part of company’s filings submitted to BSE.
Mercury Laboratories informs about closure of trading window
Mercury Laboratories has informed that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and as per Company’s Code of Conduct for regulating, monitoring, reporting of trading by insiders, trading window for dealing in securities of the Company by the Designated Persons and their relatives shall remain closed with effect from Wednesday, July 01, 2026. The trading window shall remain closed till 48 hours after the announcement of the unaudited financial results of the Company for the quarter ended on June 30, 2026. The date of the Board Meeting for considering the unaudited financial results for the quarter ended on June 30, 2026 will be intimated in due course
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Natco Pharma Ltd. is ₹903.70 as of 2026-06-25.
The market capitalisation of Natco Pharma Ltd. is ₹16,011.53 as of 2026-06-24.
The 1-year return of Natco Pharma Ltd. is 0.00% as of 2026-06-25.
The P/E ratio of Natco Pharma Ltd. is 7.57 as of 2026-06-25.
The 52-week high and low of Natco Pharma Ltd. are ₹1,226.80 and ₹789.00, respectively, as of 2026-06-25.
People Also Ask
Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.
Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.
Natco Pharma is an Indian pharmaceutical company that researches, develops, manufactures, and markets generic medicines, oncology‑focused products, active pharmaceutical ingredients (APIs), and agro‑health solutions for domestic and international markets.
NATCO is the brand and corporate name used by Natco Pharma Limited. The company does not prominently use or disclose an official expanded form of the abbreviation in its public corporate identity.
Before it became Natco Pharma Limited, the company was initially known as Natco Fine Pharmaceuticals, under which it started its operations in thepharmaceutical sector.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
